65.56
-0.69 (-1.05%)
| Previous Close | 66.25 |
| Open | 65.86 |
| Volume | 153,963 |
| Avg. Volume (3M) | 1,021,662 |
| Market Cap | 5,782,113,280 |
| Price / Sales | 955.26 |
| Price / Book | 4.93 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2026 |
| Operating Margin (TTM) | -81,161.54% |
| Diluted EPS (TTM) | -1.50 |
| Quarterly Revenue Growth (YOY) | -90.20% |
| Total Debt/Equity (MRQ) | 0.15% |
| Current Ratio (MRQ) | 30.97 |
| Operating Cash Flow (TTM) | -81.98 M |
| Levered Free Cash Flow (TTM) | -57.18 M |
| Return on Assets (TTM) | -12.85% |
| Return on Equity (TTM) | -16.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | CG Oncology, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.10 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.17% |
| % Held by Institutions | 105.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 31 Mar 2026 | 6,371,669 |
| Foresite Capital Management Vi Llc | 31 Mar 2026 | 2,221,474 |
| Seven Fleet Capital Management Lp | 31 Mar 2026 | 1,515,151 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MULAY JAMES | - | 59.55 | -1,964 | -116,956 |
| Aggregate Net Quantity | -1,964 | |||
| Aggregate Net Value ($) | -116,956 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 59.55 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MULAY JAMES | Director | 15 Jun 2026 | Automatic sell (-) | 1,964 | 59.55 | 116,956 |
| MULAY JAMES | Director | 15 Jun 2026 | Option execute | 1,964 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |